3,505 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,505 shares of the medical research company’s stock, valued at approximately $259,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. lifted its stake in Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after buying an additional 273 shares during the last quarter. Nordea Investment Management AB lifted its stake in Edwards Lifesciences by 34.6% in the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after buying an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its stake in Edwards Lifesciences by 6.7% in the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after buying an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $4,845,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $73.25 on Friday. The business’s 50-day moving average price is $72.85 and its 200 day moving average price is $69.94. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market capitalization of $43.20 billion, a PE ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 26,489 shares of company stock worth $2,002,829 in the last three months. 1.29% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Evercore ISI dropped their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. The Goldman Sachs Group upped their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Piper Sandler upped their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Finally, Truist Financial reaffirmed a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.